PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.02
Positive D/E while AXSM shows negative equity. John Neff would examine our competitive advantages in a challenging market.
8.61
Higher net debt at 1.1-1.25x AXSM's 6.90. Bruce Berkowitz would look for hidden assets justifying this higher leverage.
No Data
No Data available this quarter, please select a different quarter.
10.51
Similar current ratio to AXSM's 9.99. Guy Spier would investigate if industry liquidity norms make sense for both companies.
No Data
No Data available this quarter, please select a different quarter.